Effectiveness of Ultraporous β-Tricalcium Phosphate (Vitoss) as Bone Graft Substitute for Cavitary Defects in Benign and Low-Grade Malignant Bone Tumors

We retrospectively evaluated healing with ultrapor­ous β-tricalcium phosphate (β-TCP [Vitoss; Orthovida, Malvern, Pennsylvania]) bone graft in patients who underwent surgical excision or curettage of benign bone lesions subsequently filled with bone void filler. Twenty-nine patients were treated with curettage and ultrapor­ous β-TCP morsels. Radiologic defect size at initial postoperative presentation and subsequent visits (mini­mum follow-up, 6 months) was evaluated. Results sug­gested that an ultraporous β-TCP synthetic bone graft is effective in managing bone voids. The vast majority of patients who undergo curettage for benign bone lesions can expect to have complete or near complete healing of these defects within 6 months of their surgical procedure with use of ultraporous β-TCP morsels.